Overcoming Multidrug Resistance Through Targeting Abc Transporters: Lessons for Drug Discovery Publisher Pubmed



Feyzizadeh M¹ ; Barfar A¹ ; Nouri Z² ; Sarfraz M³ ; Zakerimilani P⁴ ; Valizadeh H⁵ Show Affiliations
Source: Expert Opinion on Drug Discovery Published:2022

Abstract

Introduction: The argument around cancer therapy is an old one. Using chemotherapeutic drugs, as one of the most effective strategies in treatment of malignancies, is restricted by various issues that progress during therapy and avoid achieving clinical endpoints. Multidrug resistance (MDR), frequently mediated by ATP-binding cassette (ABC) transporters, is one of the most recognized obstacles in the success of pharmacological anticancer approaches. These transporters efflux diverse drugs to extracellular environment, causing MDR and responsiveness of tumor cells to chemotherapy diminishes. Areas covered: Several strategies have been used to overcome MDR phenomenon. Succession in this field requires complete knowledge about features and mechanism of ABC transporters. In this review, conventional synthetic and natural inhibitors are discussed first and then novel approaches including RNA, monoclonal antibodies, nanobiotechnology, and structural modification techniques are represented. Expert opinion: With increasing frequency of MDR in cancer cells, it is essential to develop new drugs to inhibit MDR. Using knowledge acquired about ABC transporter’s structure, rational design of inhibitors is possible. Also, some herbal products have shown to be potential lead compounds in drug discovery for reversal of MDR. © 2022 Informa UK Limited, trading as Taylor & Francis Group.